CLAIMS

1. A compound of Formula I



I

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug;

wherein R_1 is a) -(C_1-C_6)alkyl optionally substituted with -CF_3, b) -C≡C-CH_3, c) -C≡C-Cl, d) -C≡C-CF_3, e) -CH_2O(C_1-C_4)alkyl optionally substituted with -CF_3 or f) -CF_3;

R_2 is a) -(C_1-C_5)alkyl, b) -(C_2-C_5)alkenyl or c) -phenyl optionally substituted with one of the following: -OH, -NR_9-C(O)-(C_2-C_4)alkyl, -CN, -Z-het, -O-(C_1-C_3)alkyl-C(O)-NR_9R_{10}, -NR_9-Z-C(O)-NR_9R_{10}, -Z-NR_9-SO_2-R_{10}, -NR_9-SO_2-het, -O-C(O)-(C_1-C_4)alkyl or -O-SO_2-(C_1-C_4)alkyl;

Z for each occurrence is independently -(C_0-C_4)alkyl;

R_3 is a) -hydrogen, b) -(C_1-C_6)alkyl optionally substituted with one to three halo, c) -(C_2-C_6)alkenyl or d) -(C_2-C_6)alkynyl optionally substituted with one to three halo;

R_4 is a) -hydrogen, b) -(C_2-C_5)alkyl-NR_5R_6 or c) -(C_0-C_5)alkyl-het;

or R_3 and R_4 are taken together with N to form het;

R_5 and R_6 are each independently a) hydrogen or b) -(C_1-C_3)alkyl;

het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with one to four R_7; provided that het is other than pyridinyl, imidazolyl or tetrazolyl;

R_7 is a) -(C_1-C_6)alkyl optionally substituted with one to three R_8, b) –Z-NR_9R_{10} or c) –Z-C(O)-NR_9R_{10};

R_8 for each occurrence is independently a) halo, b) –OH, c) oxo or d) -O(C_1-C_6)alkyl;

R_9 and R_{10} for each occurrence are independently a) -H or b) -(C_1-C_3)alkyl;

or R_9 and R_{10} are taken together with N to form het;

provided that:

1) when R_1 is –C≡C-CH_3, R_2 is phenyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-$N(CH_3)_2$, –$(CH_2)_3$-$N(CH_3)_2$, –$(CH_2)_2$-pyrrolidinyl optionally substituted with methyl, –$(CH_2)_3$-pyrrolidinyl or –$(CH_2)_2$-morpholinyl;

2) when R_1 is –C≡C-CH_3, R_2 is –CH_2-CH=CH_2 and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-pyrrolidinyl;

3) when R_1 is –C≡C-CH_3, R_2 is propyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-$N(CH_3)_2$ or –$(CH_2)_2$-pyrrolidinyl;

4) when R_1 is –C≡C-CH_3, R_2 is butyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-$N(CH_3)_2$, –$(CH_2)_2$-pyrrolidinyl or –$(CH_2)_2$-morpholinyl; and

5) when R_1 is –C≡C-CH_3, R_2 is pentyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-morpholinyl or –$(CH_2)_2$-pyrrolidinyl.

2. A compound of claim 1 of Formula II



II

a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;

wherein R_1 is a) -(C_1-C_6)alkyl optionally substituted with -CF_3, b) -C≡C-CH_3, c) –CF_3 or d) –CH_2O(C_2-C_4)alkyl.

3. A compound of claim 2 wherein R_1 is a) –$CH_2CH_2CH_3$, b) -C≡C-CH_3 or c) –CF_3.

4. A compound of claim 3

wherein R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

Sub A'

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

5. A compound of claim 4

wherein R_3 is a) methyl, b) ethyl, c) propyl or d) isopropyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

6. A compound of claim 5

wherein R_3 is a) methyl or b) ethyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

R_5 and R_6 are each methyl.

7. A compound of claim 3

wherein R_3 is a) hydrogen, b) methyl or c) ethyl;

R_4 is -(C_0-C_4)alkyl-het;

het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl, d) piperazinyl, e) hexahydro-azepinyl, f) azabicyclo[2.2.2]oct-3-yl, g) azabicyclo[3.2.1]oct-3-yl, h) 3,6-diazabicyclo[3.1.1]heptyl or i) 2,5-diazabicyclo[2.2.1]heptyl;

the above het groups are optionally substituted with one to four R_7;

R_7 is a) methyl, b) ethyl or c) $-NR_9R_{10}$;

R_9 and R_{10} are each independently methyl or ethyl.

8. A compound of claim 7

wherein R_3 is a) hydrogen, b) methyl or c) ethyl;

R_4 is -(C_0-C_3)alkyl-het;

het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl, d) hexahydro-azepinyl, or e) azabicyclo[3.2.1]oct-3-yl;

the above het groups are optionally substituted with one or two R_7;

wherein R_7 is a) methyl or b) ethyl.

9. A compound of claim 8

wherein R_3 is a) methyl or b) ethyl;

R_4 is -(C_0-C_3)alkyl-het;

het is a) pyrrolidinyl, b) piperidinyl, c) hexahydro-azepinyl, or d) azabicyclo[3.2.1]oct-3-yl;

the above het groups are optionally substituted with one R_7;

wherein R_7 is a) methyl or b) ethyl.

10. A compound of claim 3 wherein R_3 and R_4 are taken together with N to form het;

wherein het is a) piperazinyl, b) pyrrolidinyl, c) piperidinyl, d) 2,5-diazabicyclo[2.2.1]heptyl, e) azetidinyl, f) 1,4-diazabicyclo[3.2.2]nonanyl, g) 3,6-diazabicyclo[3.2.2]nonanyl, h) octahydro-pyrido[1,2-a]pyrazinyl or i) hexahydro-1,4-diazepinyl;

the above het groups are optionally substituted with one or two R_7;

R_7 is a) $-(C_1-C_2)$alkyl optionally substituted with one or two R_8, b) $-(C_0-C_2)$alkyl-NR_9R_{10} or c) -Z-C(O)-NR_9R_{10};

R_8 is -OH;

R_9 and R_{10} are each independently a) hydrogen b) methyl or c) ethyl;

or R_9 and R_{10} are taken together with N to form a) pyrrolidinyl or b) piperidinyl.

11. A compound of claim 10 wherein R_3 and R_4 are taken together with N to form het;

wherein het is a) pyrrolidinyl, b) piperidinyl or c) azetidinyl;

the above het groups are optionally substituted with one R_7;

R_7 is $-CH_2-NR_9R_{10}$;

R_9 and R_{10} are each independently a) methyl or b) ethyl;

or R_9 and R_{10} are taken together with N to form a) pyrrolidinyl or b) piperidinyl.

12. A compound of claim 1

wherein R_1 is a) $-CH_2CH_2CH_3$, b) -C≡C-CH_3 or c) $-CF_3$;

R_2 is a) $-(C_1-C_5)$alkyl or b) $-(C_2-C_5)$alkenyl;

R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is $-(C_2-C_3)$alkyl-NR_5R_6;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

13. A compound of claim 12

wherein R_2 is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

R_3 is a) hydrogen, b) methyl or c) ethyl,

R_5 and R_6 are each independently a) methyl or b) ethyl.

14. A compound of claim 1

wherein R_1 is a) $-CH_2CH_2CH_3$, b) -C≡C-CH_3 or c) $-CF_3$;

R_2 is a) $-(C_1-C_5)$alkyl or b) $-(C_2-C_5)$alkenyl;

Sub A1

R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is -(C_0-C_4)alkyl-het;

het is a) morpholinyl, b) pyrrolidinyl, c) piperidinyl or d) piperazinyl;

the above het groups are optionally substituted with one or two R_7;

R_7 is a) methyl, b) ethyl or c) –NR_9R_{10};

R_9 and R_{10} are each independently methyl or ethyl.

15. A compound of claim 14

wherein R_2 is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

R_3 is a) hydrogen, b) methyl or c) ethyl;

R_4 is -(C_2-C_3)alkyl-het;

het is a) morpholinyl or b) pyrrolidinyl;

the above het groups are optionally substituted with one or two R_7;

wherein R_7 is a) methyl or b) ethyl.

16. A compound of claim 1

wherein R_1 is a) –$CH_2CH_2CH_3$, b) -C≡C-CH_3 or c) –CF_3;

R_2 is a) -(C_1-C_5)alkyl or b) -(C_2-C_5)alkenyl;

R_3 and R_4 are taken together with N to form het;

het is a) piperazinyl, b) pyrrolidinyl or c) piperidinyl;

the above het groups are optionally substituted with one or two R_7;

R_7 is a) –(C_1-C_2)alkyl optionally substituted with one or two R_8, b) –(C_0-C_2)alkyl-NR_9R_{10} or c) -Z-C(O)-NR_9R_{10};

R_8 is -OH;

R_9 and R_{10} are each independently a) hydrogen b) methyl or c) ethyl;

or R_9 and R_{10} are taken together with N to form a) pyrrolidinyl or b) piperidinyl.

17. A compound of claim16

wherein R_2 is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

het is a) pyrrolidinyl or b) piperidinyl;

the above het groups are optionally substituted with one R_7;

R_7 is –CH_2-NR_9R_{10};

R_9 and R_{10} are each independently a) methyl or b) ethyl;

or R_9 and R_{10} are taken together with N to form a) pyrrolidinyl or b) piperidinyl.

18. A compound of claim 1 wherein in Formula I –CH_2-R_2 is ethenyl or ethynyl.

Sub A1

19. A compound of claim 4 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

carbamic acid, [3-(diethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

20. A compound of claim 6 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

21. A compound of claim 8 selected from the group consisting of:

carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [2-(1-piperidinyl)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(hexahydro-1*H*-azepin-1-yl)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

Sub A1

carbamic acid, [2-(1-piperidinyl)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, (1-ethyl-3-piperidinyl)-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl;

carbamic acid, [(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(hexahydro-1*H*-azepin-1-yl)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [[(2*R*)-1-ethyl-2-pyrrolidinyl]methyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(1-piperidinyl)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [[(2*S*)-1-ethyl-2-pyrrolidinyl]methyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [[(2*R*)-1-ethyl-2-pyrrolidinyl]methyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [2-(4-morpholinyl)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

carbamic acid, [3-(4-morpholinyl)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

22. A compound of claim 11 selected from the group consisting of:

1-pyrrolidinecarboxylic acid, 2-(1-pyrrolidinylmethyl)-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

1-piperidinecarboxylic acid, 2-(1-piperidinylmethyl)-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

1-piperidinecarboxylic acid, 2-[(dimethylamino)methyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

1-piperidinecarboxylic acid, 2-[(diethylamino)methyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

1-azetidinecarboxylic acid, 3-(1-piperidinyl)-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

23. Carbamic acid, (2,2,6,6-tetramethyl-4-piperidinyl)-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester, a compound of claim 7.

24. A compound of claim 13 selected from the group consisting of:

carbamic acid, (3-dimethylaminopropyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)ethyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester; and

carbamic acid, (2-dimethylaminoethyl)-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

25. A compound of claim 15 selected from the group consisting of:

carbamic acid, (3-morpholin-4-yl-propyl)-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-pyrrolidin-1-yl-ethyl)-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester; and

carbamic acid, (2-morpholin-4-yl-ethyl)-,(4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

26. 2-Pyrrolidin-1-ylmethylpyrrolidine-1-carboxylic acid, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynylphenanthren-2-yl ester, a compound of claim 17.

27. A method for the treatment of a glucocorticoid receptor-mediated disease or condition in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

28. The method of claim 27 wherein the glucocorticoid receptor-mediated disease or condition is selected from the group consisting of obesity, diabetes, depression, anxiety and neurodegeneration.

29. The method of claim 28 wherein the condition is obesity.

30. The method of claim 29 which further comprises administering a β_3 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist.

31. The method of claim 30 wherein the eating behavior modifying agent is orlistat or sibutramine.

32. The method of claim 28 wherein the disease is diabetes.

33. The method of claim 32 which further comprises administering an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylurea, glipizide, glyburide, or chlorpropamide.

34. The method of claim 27 wherein the glucocorticoid receptor-mediated disease is an inflammatory disease.

35. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

36. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound, or prodrug;

a second compound, said second compound being a β_3 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist; and

a pharmaceutical carrier, vehicle or diluent.

37. A kit comprising:

a) a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound, or prodrug and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form;

b) a second compound, said second compound being a β_3 agonist, a thyromimetic agent, an eating behavior modifying agent or a NPY antagonist; and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and

c) a container for containing said first and second dosage forms; wherein the amounts of said first and second compounds result in a therapeutic effect.

38. A method for inducing weight loss in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.

39. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising:

a first compound, said first compound being a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug;

a second compound, said second compound being an aldose reductase inhibitor, a glycogen phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, insulin, a sulfonylurea, glipizide, glyburide, or chlorpropamide; and

a pharmaceutical carrier, vehicle or diluent.

40. A method for the treatment of an inflammatory disease in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1, a prodrug of said compound or a pharmaceutically acceptable salt of said compound or prodrug.

41. The method of claim 40 wherein the inflammatory disease is selected from the group consisting of arthritis, asthma, rhinitis and immunomodulation.